Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2014 - 2023)

Capricor Therapeutics (CAPR) posted quarterly Non-Current Deffered Revenue of $953470.0 for Q3 2023, down 90.32% year-over-year from $9.8 million in Q3 2022, and down 70.5% quarter-over-quarter from $3.2 million in Q2 2023.

Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2014 - 2023) Analysis & Trends

Capricor Therapeutics' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $953470.0 for Q3 2023.

  • In Q3 2023, Non-Current Deffered Revenue fell 90.32% year-over-year to $953470.0; the TTM figure through Sep 2023 stood at $953470.0 (down 90.32% YoY), while the FY2022 annual figure was $9.5 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue for Q3 2023 stood at $953470.0, down from $3.2 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $20.3 million in Q1 2022, with the low at $953470.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Capricor Therapeutics 383.47 Mn 383.47 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2023 953,470.00
Jun 30, 2023 3.23 Mn
Mar 31, 2023 5.45 Mn
Dec 31, 2022 9.47 Mn
Sep 30, 2022 9.85 Mn
Jun 30, 2022 14.30 Mn
Mar 31, 2022 20.30 Mn
Dec 31, 2015 911,458.00
Sep 30, 2015 1.82 Mn
Jun 30, 2015 2.73 Mn
Mar 31, 2015 3.12 Mn
Dec 31, 2014 4.17 Mn
Sep 30, 2014 5.21 Mn
Jun 30, 2014 6.25 Mn
Mar 31, 2014 7.29 Mn